Champions Oncology, Inc. (CSBR) Stock

Champions Oncology, Inc. specializes in developing and offering innovative technology solutions and products designed to personalize the development and application of oncology drugs across the United States. Central to its offerings is the Tumorgraft Technology Platform, which revolutionizes cancer care by implanting human tumors into immune-deficient mice. This platform enables the company to provide personalized treatment strategies tailored to individual patient profiles.

Through its Tumorgraft Technology Platform, Champions Oncology not only delivers personalized cancer care but also offers Translational Oncology Solutions to pharmaceutical and biotechnology companies. These solutions leverage the company's advanced technology to support and enhance the drug development process, facilitating more effective treatments for cancer patients.

Additionally, Champions Oncology provides Lumin Bioinformatics, a comprehensive software platform and data tool. Lumin Bioinformatics integrates insights derived from extensive research services and clinical studies, offering valuable information through annual subscription services. Leveraging internet channels, word of mouth, and a dedicated sales force, the company effectively markets its products to patients and healthcare providers. Founded in 1985 and headquartered in Hackensack, New Jersey, Champions Oncology, Inc. continues to drive innovation in personalized oncology, committed to advancing cancer treatment and improving patient outcomes.